Baxter International (BAX) PT Lowered to $90 at Stifel

July 29, 2021 1:06 PM EDT
Get Alerts BAX Hot Sheet
Price: $80.85 +0.07%

Rating Summary:
    20 Buy, 8 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Rick Wise lowered the price target on Baxter International (NYSE: BAX) to $90.00 (from $95.00) while maintaining a Buy rating.

The analyst commented, "Overall, Baxter’s 2Q21 results seemed mixed, if not slightly-disappointing. Total sales were basically in-line with Stifel/Consensus (+8% operationally), aided by COVID vaccine manufacturing sales ($40M vs full-year guidance $50M-$100M). Base business segment performance varied. Medication Delivery and Advanced Surgery were the only solid outperformers with growth driven by hospital admission/surgical volume recovery. Renal and Pharmaceuticals disappointed with OUS Renal sales negatively impacted by y/y ESRD patient volume declines (both PD and HD), and US Pharmaceuticals unexpectedly-challenged by increased generic injectable competition. EPS outperformance was driven by lower SG&A/etc. For now, we look to a perhaps more-critical-than-usual September analyst day where BAX should articulate drivers of better growth (perhaps MSD+) and expanding operating margins. If 2H21 recovery progresses, and the analyst day successfully re-establishes a more clear-cut path to better growth/margins, the post-report stock weakness may prove to be a more-attractive entry point than today’s “mixed” 2Q operating performance might suggest."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities